Patents Assigned to HARPOON THERAPEUTICS, INC.
-
Patent number: 11976125Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.Type: GrantFiled: January 15, 2021Date of Patent: May 7, 2024Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin
-
Patent number: 11807692Abstract: Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.Type: GrantFiled: August 21, 2020Date of Patent: November 7, 2023Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Richard J. Austin
-
Patent number: 11623958Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.Type: GrantFiled: January 27, 2020Date of Patent: April 11, 2023Assignee: HARPOON THERAPEUTICS, INC.Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan Lemon
-
Patent number: 11607453Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.Type: GrantFiled: January 27, 2020Date of Patent: March 21, 2023Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
-
Patent number: 11535668Abstract: Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.Type: GrantFiled: February 28, 2018Date of Patent: December 27, 2022Assignee: HARPOON THERAPEUTICS, INC.Inventors: Patrick Baeuerle, Holger Wesche
-
Patent number: 11453716Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.Type: GrantFiled: October 16, 2018Date of Patent: September 27, 2022Assignee: HARPOON THERAPEUTICS, INC.Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
-
Patent number: 11180563Abstract: Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.Type: GrantFiled: February 19, 2021Date of Patent: November 23, 2021Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Richard J. Austin
-
Patent number: 11136403Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.Type: GrantFiled: October 12, 2018Date of Patent: October 5, 2021Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin
-
Publication number: 20210269530Abstract: Disclosed herein is a conditionally active target binding protein that contains a first binding domain that binds to a bulk serum protein and sterically occludes binding of a second binding domain to its target. Pharmaceutical compositions comprising the conditionally active binding proteins disclosed herein and methods of using such compositions are further provided.Type: ApplicationFiled: May 14, 2019Publication date: September 2, 2021Applicant: Harpoon Therapeutics, Inc.Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE
-
Patent number: 10954311Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.Type: GrantFiled: June 22, 2017Date of Patent: March 23, 2021Assignee: HARPOON THERAPEUTICS, INC.Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
-
Patent number: 10927180Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.Type: GrantFiled: October 12, 2018Date of Patent: February 23, 2021Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin
-
Patent number: 10849973Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.Type: GrantFiled: November 22, 2017Date of Patent: December 1, 2020Assignee: HARPOON THERAPEUTICS, INC.Inventors: Robert Dubridge, Pui Seto, Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Bryan D. Lemon, Richard J. Austin
-
Patent number: 10844134Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.Type: GrantFiled: November 22, 2017Date of Patent: November 24, 2020Assignee: HARPOON THERAPEUTICS, INC.Inventors: Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Pui Seto
-
Patent number: 10815311Abstract: Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.Type: GrantFiled: September 25, 2019Date of Patent: October 27, 2020Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Richard J. Austin
-
Patent number: 10730954Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.Type: GrantFiled: May 11, 2018Date of Patent: August 4, 2020Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
-
Patent number: 10543271Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.Type: GrantFiled: May 11, 2018Date of Patent: January 28, 2020Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
-
Patent number: 10544221Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.Type: GrantFiled: May 19, 2017Date of Patent: January 28, 2020Assignee: HARPOON THERAPEUTICS, INC.Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
-
Patent number: 10100106Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.Type: GrantFiled: May 19, 2017Date of Patent: October 16, 2018Assignee: HARPOON THERAPEUTICS, INC.Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
-
Patent number: 10066016Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.Type: GrantFiled: September 14, 2017Date of Patent: September 4, 2018Assignee: HARPOON THERAPEUTICS, INC.Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
-
Patent number: 9708412Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.Type: GrantFiled: May 20, 2016Date of Patent: July 18, 2017Assignee: HARPOON THERAPEUTICS, INC.Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche